Advanced or Metastatic Clear Cell Renal Cell CarcinomaPhase 1NCT07564232
LNK001 Dual-Target CAR T Cells
LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
What the film says
This trial is for adults with advanced or metastatic kidney cancer, clear cell or sarcomatoid.
The idea: give standard immunotherapy, nivolumab and ipilimumab, with or without EXL01. EXL01 is a live biotherapeutic product, a capsule containing a strain of gut bacteria called Faecalibacterium prausnitzii, taken by mouth. Gut bacteria may affect how well immunotherapy works.
The study looks at safety and effectiveness.
This phase 1 study plans 33 patients. At City of Hope in Duarte, California, Sumanta Pal leads it.
Public record; not medical advice.
Sources behind this film
Adults; metastatic clear cell RCC; Nivolumab + ipilimumab ± EXL01; F. prausnitzii; by mouth; Gut bacteria may affect immunotherapy; Safety and effectiveness (+1 more lines)
The drug
PRIMARY OBJECTIVE: I. To evaluate the effects of Faecalibacterium prausnitzii-containing bacterial strain formulation EXL01 (EXL01) (in combination with nivolumab/ipilimumab) on systemic immunomodulation in patients with mRCC. SECONDARY OBJECTIVES: I. To evaluate the safety and tolerability of EXL01 (in combination with nivolumab/ipilimumab) in the treatment of patients with mRCC. II. To evaluate the effect of EXL01 on the clinical efficacy of nivolumab/ipilimumab.
EXPLORATORY OBJECTIVES: I. To determine the effect of EXL01 on gut microbiome diversity and function. II. To determine the effect of EXL01 on systemic immunodulation. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: CYCLES 1-4: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle and receive EXL01 orally (PO) once daily (QD) on days 1-21 of each cycle.
The study
This phase I trial tests the safety and effectiveness of nivolumab and ipilimumab with and without EXL01 for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread.
EXL01 is a live biotherapeutic product containing a strain of bacteria called Faecalibacterium prausnitzii. It may enhance a patient's response to treatment with immune checkpoint inhibitors like nivolumab and ipilimumab by altering the composition of the bacteria in the gut. Adding EXL01 to treatment with nivolumab and ipilimumab may be safe and more effective than giving nivolumab and ipilimumab alone.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.